For example, venetoclax induces MCL-1 up-regulation in AML cells,29 and recently MCL-1 antagonists have been shown to potentiate MCL-1 accumulation in chronic lymphocytic leukemia (CLL) cells by diminishing MCL-1 ubiquitination and degradation.30 Interestingly, MCL-1 inhibitors enhance the ability of Src antagonists to inhibit breast cancer cell metastasis.31 Together, these studies provide a rationale for employing Src inhibitors to reverse MCL-1 accumulation in AML cells induced by MCL-1 inhibitors. Here, SRC is linked to B-cell chronic lymphocytic leukemia.